The Indian drugs regulator and Biocon Biologics find themselves in a messy situation after the country’s premier investigating agency said that it was probing allegations of graft pertaining to trial-related permissions for the firm’s insulin aspart.
India’s Central Bureau of Investigation (CBI) said that it had apprehended a joint drugs controller in the act of allegedly...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?